Artiva Biotherapeutics Inc (ARTV)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.22+0.48%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
Research Workspace
Put ARTV beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisThis stock is volatile — it swings about 2% on a typical day and fell roughly 69% in its worst 12-month stretch.
View RiskArtiva's AlloNK program has to keep advancing to justify the price. The company is unprofitable with weak recent financial performance. Revenue growth is not visible in the available data. The latest quarter showed a small earnings beat. No valuation multiple is available to compare against peers. The stock trades without a clear earnings yield. Two patient deaths forced a halt to the cell therapy trial. The company cut its workforce by 94 percent. This event fundamentally undermines the AlloNK development thesis. Peer multiples imply a price about 12% above where it trades. This read is provisional.
Trailing returns as of 2026-11-04. ARTV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering ARTV (as of Nov 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare ARTV with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ARTV Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put ARTV next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Discontinue AlloNK development and close out clinical studies
Reported program halt and workforce cuts align with discontinuing AlloNK and preserving capital.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Threatens: Advance AlloNK clinical development with initial data presentations
Discontinuation after patient deaths and a 94% workforce cut fundamentally undermine AlloNK development and the investment thesis.
Threatens: Advance AlloNK clinical development with initial data presentations
Reported trial halt directly threatens AlloNK clinical development and planned initial response data.
Advances: Advance AlloNK clinical development with initial data presentations
Planned presentation of AlloNK data advances clinical disclosure, but is not itself a results catalyst.
FDA RMAT designation may support development, but does not establish approval or clinical efficacy.
Insider selling raises concerns about management confidence.
Insider selling raises concerns about management confidence.
Insider selling raises concerns about management confidence.